Europe's Pharma Supply Chain Dilemma: The High Price of Reliance on China and Inflation

Europe's cost-optimized supply chains are now forced to pay the price for resilience as geopolitical risks and supply security concerns mount. Richard Saynor, CEO of Sandoz, notes a growing realization among business and political leaders regarding the vulnerability of critical supply chains, yet the challenge of translating this into action persists. Generic and biosimilar drugs, which constitute roughly 70% of the drugs used across Europe, account for only 10% to 20% of the total drug bill, highlighting the precarious balance of the market.

The Heavy Toll of Asian Dependency

Very few of the complex drugs, particularly non-biologics, are manufactured in Europe. Almost all key starting materials are imported from China or India, with virtually no domestic manufacturing because payers have driven margin pricing to the bottom.

■Without generic companies, there is effectively no healthcare system in Europe.

■In the pursuit of lower costs, the value of sustainability and security was overlooked.

■70% of volume accounting for just 20% of cost indicates immense pressure on the sector.

Logistics Bottlenecks Within Borders

The COVID-19 pandemic prioritized supply sovereignty, exposing weaknesses. Ironically, moving products from Italy to Austria often presents more problems than importing from India into Europe, as governments prioritize protecting patents and national interests over a collective European supply framework.

In times of crisis, solutions can be found. During the pandemic, 50-100 million packs of hydroxychloroquine were delivered to 35-40 markets in a very short period because regulators waived standard requirements, proving that mechanisms exist to solve problems when necessary.

The Reshoring Illusion vs. Economic Reality

Reshoring all of Europe's supply chains is a great aspiration but completely unrealistic. People will build infrastructure and manufacture raw materials in Europe only if the economic environment rewards it. Boards of directors will not authorize capital deployment without a sensible return on investment.

Many industries are set to face an inflationary shock over the next six months to a year. Rising costs of materials, fuel, and interest rates mean the cost of doing business is increasing. The reality is that these costs will be passed on to customers, making medicines across the board more expensive.

The Oncoming Inflationary Shock

Europe excels at legislation but doesn't always consider all implications. We risk entering a world where the security of supply for critical medicines cannot be guaranteed due to a lack of economic incentives for long-term capital investment.

■Europe is getting older, sicker, and, like it or not, poorer.

■Without a healthy society, everything else crumbles.

■We sell products like penicillin more cheaply today than a Mars bar or chewing gum, often forgetting their value despite understanding production costs.

As global supply chain strategists, we characterize this situation as a "strategic dilemma." Europe's dependency on China and India for APIs (Active Pharmaceutical Ingredients) is not merely a trade imbalance but a direct reflection of geopolitical risks in maritime routes impacting healthcare systems. Fluctuations in freight markets and chokepoints at critical junctions like Suez or Panama will impose severe costs on such a "Just-in-Time" focused sector. Companies are now forced to pivot from "cost" to "flexibility" and "security" based rotations, which will drive up freight demand and inventory costs in the medium term.